Introduction Dosing of antibiotics in people with cystic fibrosis (CF) is challenging, due to
altered pharmacokinetics, difficulty of lung tissue penetration, and increasing presence of …

Cystic fibrosis affects several organs, predisposing patients to severe bacterial respiratory
infections, including those caused by methicillin-resistant Staphylococcus aureus. Cystic …

Antibiotic therapy plays a central role in the medical management of patients with cystic
fibrosis. While totally convincing efficacy data are lacking, antibiotics probably have a …

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic
fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics …

Antibiotics are administered to cystic fibrosis patients for chronic endobronchial infection
complicated by frequent exacerbations. Agents active against Staphylococcus aureus …

Antibacterials play a central role in the medical management of patients with cystic fibrosis
(CF). Administration of adequate dosages of antibacterials results in pronounced beneficial …

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main
cause of death. Treatment of lung disease to reduce the impact of infection, inflammation …

Bacteria adapt to growth in lungs of patients with cystic fibrosis (CF) by selection of
heterogeneously resistant variants that are not detected by conventional susceptibility …

The disposition of many drugs in cystic fibrosis is abnormal compared with healthy
individuals. In general, changes include an increased volume of distribution expressed in …

Chronic pulmonary infections contribute significantly to the morbidity and mortality of
patients with CF. The primary pathogens are Pseudomonas aeruginosa (PA) and …